Uncategorized

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs

Supernus and Indivior merge to create CNS mega-company with 11 approved drugs

Published

on

Supernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version